Publications by the researcher in collaboration with Edel del Barco Morillo (15)

2025

  1. Corrigendum to “Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review” [Clin. Translat. Radiat. Oncol. 52 (2025) 100930](S2405630825000205)(10.1016/j.ctro.2025.100930)

    Clinical and Translational Radiation Oncology

  2. Current and future perspectives in clinical practice in KRAS-mutated non-small cell lung cancer: a literature review

    Precision Cancer Medicine, Vol. 7, pp. 1-13

  3. Neoadjuvant chemoimmunotherapy or chemoradiotherapy in stage III non-small cell lung cancer: crossing the Rubicon?

    Chinese Clinical Oncology, Vol. 14, Núm. 5

  4. Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study

    Translational Lung Cancer Research, Vol. 14, Núm. 7, pp. 2494-2508

2024

  1. Cancer-Associated Thrombotic Microangiopathy: Literature Review and Report of Five Cases

    Life, Vol. 14, Núm. 7

  2. Cuidados continuos en oncología (III): infecciones en el paciente con cáncer, neutropenia febril

    Oncología clínica (Arán), pp. 175-188

  3. Current and future perspectives in clinical practice in KRAS-mutated non-small cell lung cancer: a literature review

    Precision Cancer Medicine, pp. 1-13

  4. Cáncer de cabeza y cuello

    Oncología clínica (Arán), pp. 259-271

  5. Cáncer de pulmón

    Oncología clínica (Arán), pp. 227-257

  6. Diagnóstico nosológico y de extensión. Factores pronósticos

    Oncología clínica (Arán), pp. 59-71

  7. Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 4

  8. Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50%

    Translational Lung Cancer Research, Vol. 13, Núm. 10, pp. 2649-2659

2023

  1. Biomarkers for immunotherapy in non-small cell lung cancer: a current and future reality

    Precision Cancer Medicine

  2. Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

    Cancers, Vol. 15, Núm. 17

  3. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6